Business Context and Reporting Period
This Form 6-K filing by IM Cannabis Corp. covers the month of July 2026. The registrant, headquartered in Kibbutz Glil Yam, Israel, is a foreign private issuer reporting a specific corporate financing event rather than periodic financial results.
Key Financial Metrics and Transaction Details
The filing details a convertible note financing transaction closed on July 1, 2026. Key financial terms include:
- Gross Proceeds: US$225,000 (Subscription Amount).
- Net Proceeds: US$202,500, intended for general corporate purposes.
- Instrument: A convertible note bearing 8.0% annual interest (increasing to 14.0% upon an Event of Default).
- Repayment Terms: The note is not repayable in cash; obligations are satisfied solely through the issuance of common shares upon conversion.
- Conversion Price: The lower of a Fixed Price (US$0.152) or a Variable Price (90% of the lowest 20-day VWAP), subject to a Floor Price of US$0.0303.
- Warrant Component: Issuance of a warrant to purchase up to 1,483,386 common shares at an exercise price of CAD$0.22 per share.
- Warrant Terms: Exercisable immediately for five years (until July 1, 2031), with a four-month trading lock-up period.
The filing does not provide revenue, profit, cash flow, margins, or existing debt levels for the period.
Material Changes
The primary material change is the increase in debt obligations and potential equity dilution resulting from the issuance of the convertible note and warrant. The company has incurred a new liability of US$225,000 principal, which will convert to equity based on market conditions. No comparative financial data for the prior period is provided in this document.
Guidance, Outlook, and Risks
Management Commentary: The company intends to use net proceeds for general corporate purposes. Management has committed to filing a resale registration statement (Form F-3) within 30 trading days and using commercially reasonable efforts to have it effective within 60 to 90 days.
Risks and Contingencies: The filing includes extensive forward-looking statement disclaimers and highlights significant risks, including:
- Regulatory compliance in a highly regulated industry.
- Geopolitical risks, specifically the impact of war and conflict in Eastern Europe and the Middle East on operations in Israel.
- Reliance on third-party supply agreements and key personnel.
- Ability to maintain Nasdaq Capital Market listing requirements.
- Uncertainty regarding profitability and the ability to achieve sales growth in Israel and Germany markets.
Investor Verification Checklist
- Verify the effective date of the Form F-3 resale registration statement to confirm the liquidity timeline for the investor's shares.
- Monitor the company's stock price relative to the Fixed Price (US$0.152) and Floor Price (US$0.0303) to assess potential dilution upon conversion.
- Review the company's latest Form 20-F for current liquidity positions and existing debt levels not detailed in this 6-K.
- Assess the impact of ongoing geopolitical conflicts in Israel on the company's operational continuity and supply chain.
- Confirm the status of the company's medical cannabis licenses in Israel and Germany.